SCHEDULE: Perceptive Advisors Reduces Lyra Therapeutics Stake to 5.5%

Sentiment:

Beneficial Ownership Amendment 18 November 2025 4:14 PM

Perceptive Advisors and its affiliates have reduced their beneficial ownership in Lyra Therapeutics, Inc. to 5.5% through recent share sales.

Worse than expectedPerceptive Advisors and its affiliates reduced their beneficial ownership from an unspecified previous percentage (implied to be higher than 5.5%) to 5.5% through multiple sales transactions, indicating a decrease in institutional confidence.

Summary

Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd., and Perceptive LS (A), LLC (collectively, the "Reporting Persons") have filed an Amendment No. 9 to their Schedule 13D.
The filing reports a reduction in their aggregate beneficial ownership of Lyra Therapeutics, Inc. common stock.
As of the filing date, Perceptive Advisors LLC and Joseph Edelman beneficially own 98,301 shares, representing 5.5% of the outstanding common stock.
Perceptive Life Sciences Master Fund, Ltd. beneficially owns 88,374 shares (5.0%), and Perceptive LS (A), LLC beneficially owns 9,927 shares (0.6%).
The percentage ownership is based on 1,774,882 outstanding shares of Common Stock as of November 7, 2025, as reported by Lyra Therapeutics, Inc. in its Quarterly Report on Form 10-Q filed on November 12, 2025.
Since the filing of Amendment No. 8 on November 13, 2025, the Reporting Persons have engaged in several sale transactions.
On November 14, 2025, Perceptive Life Sciences Master Fund, Ltd. sold 28,242 shares at a weighted average price of $3.8942, and Perceptive LS (A), LLC sold 3,173 shares at $3.8942.
On November 17, 2025, Perceptive Life Sciences Master Fund, Ltd. sold 3,021 shares at a weighted average price of $3.85, and Perceptive LS (A), LLC sold 339 shares at $3.85.
On November 18, 2025, Perceptive Life Sciences Master Fund, Ltd. sold 5,222 shares at a weighted average price of $3.6689, and Perceptive LS (A), LLC sold 587 shares at $3.6689.

Sentiment

Score: 3

Explanation: The filing indicates a significant reduction in beneficial ownership by a major institutional investor, Perceptive Advisors, through multiple share sales, which can be perceived negatively by the market.

Negatives

A significant institutional investor, Perceptive Advisors, has reduced its stake in Lyra Therapeutics, Inc. through multiple share sales.
The sales occurred at decreasing weighted average prices over three trading days, from $3.8942 on November 14, 2025, to $3.6689 on November 18, 2025.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Lyra Therapeutics or the reporting persons regarding the company's future prospects.

Industry Context

Perceptive Advisors is a prominent investment firm specializing in the life sciences sector. A reduction in their stake in a biotech company like Lyra Therapeutics could be interpreted by the market as a re-evaluation of the company's investment thesis or a strategic portfolio adjustment within the competitive biotechnology industry.

Stakeholder Impact

Shareholders may experience negative sentiment and potential downward pressure on the stock price due to the reduction in stake by a significant institutional investor.

Key Dates

Date	Description
11/07/2025	Date for which 1,774,882 outstanding shares of Common Stock were reported by the Issuer.
11/12/2025	Issuer filed its Quarterly Report on Form 10-Q with the SEC.
11/13/2025	Filing date of Amendment No. 8 to the Schedule 13D.
11/14/2025	Date of event requiring this filing; Perceptive affiliates sold 31,415 shares at $3.8942 weighted average price.
11/17/2025	Perceptive affiliates sold 3,360 shares at $3.85 weighted average price.
11/18/2025	Perceptive affiliates sold 5,809 shares at $3.6689 weighted average price; Filing date of this Amendment No. 9.

Recommendation

sell

Perceptive Advisors, a prominent life sciences investor, significantly reduced its stake in Lyra Therapeutics through multiple share sales. This action by a sophisticated institutional investor often signals a diminished conviction in the company's near-term prospects or a strategic reallocation of capital, which could exert downward pressure on the stock price and warrants a 'sell' recommendation for investors.

Keywords

Lyra Therapeutics, Perceptive Advisors, Joseph Edelman, Schedule 13D, beneficial ownership, institutional investor, share sale, biotech, common stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.